

Fig. 1A




Fig. 1B




Fig. 1C




Fig. 2A

Human CD4 T cells from hu-PBL-SCID-spl
Immunized with





Fig. 2B



Lymphocytes from hu-PBL-SCID mice
immunized with:

Fig. 3




Fig. 4





Fig. 5

HIV-1 copies/10000 actin copies



HIV-1 standard




Fig. 6A





Fig. 6B




Fig. 7A




Fig. 7B




Fig. 7C




Fig. 8




Fig. 9

TABLE 1 Protection of hu-PBL-SCID-spl mice against HIV-1 infection by immunization with HIV-1-pulsed DC.

hu-PBL-SCID-spl mice immunized with	n	#provirus ¹ (x 10 ⁻³)	culture p24 ² (ng/ml)	serum human chemokine (ng/ml) ³		
				MIP-1 α	MIP-1 β	RANTES
Donor 1						
OVA	8	10.9 \pm 5.2	60.3 \pm 23.9	nd	nd	nd
HIV-1 _{JR-CSF}	4	<10	<0.2	nd	nd	nd
HIV-1 _{NL4-3}	4	<10	<0.2	nd	nd	nd
Donor 2						
OVA	4	7.8 \pm 4.1	9.5 \pm 7.6	1.65 \pm 0.47	1.63 \pm 0.05	0.19 \pm 0.05
HIV-1 _{JR-CSF}	4	<10	<0.2	1.16 \pm 0.08	1.71 \pm 0.14	0.11 \pm 0.05
HIV-1 _{NL4-3}	4	<10	<0.2	0.62 \pm 0.10	0.79 \pm 0.29	0.12 \pm 0.09

The hu-PBL-SCID-spl mice immunized with either DC-OVA or DC-AT-2-inactivated HIV-1 particles were infected with HIV-1_{JR-CSF}. After 7 days, serum and lymphocyte samples recovered from spleen and peritoneal cavity of hu-PBL-SCID-spl mice were examined for HIV-1 infection and serum chemokine levels.

¹HIV-1 provirus copy number of the fresh samples per total recovered cells from individual mouse.

²HIV-1 p24 concentration in the supernatants of the lymphocytes cultured at 1 x 10⁶ cells/ml for 5 days.

³Human chemokine concentrations in the serum samples as determined by ELISA.